Recruiting
A Multiple Dose Study to Assess the Safety and Tolerability of BMS-963272 in Obese But Otherwise Healthy Adults - MB006-017
Updated: 10 October, 2019 | ClinicalTrials.gov
Print Friendly Summary
Trial Details
Phase
Gender(s)
Age Range
Location(s)
Recruiting
Treatment Options
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: - Participants must be in good general health, in the opinion of the investigator, with no clinically significant deviation from normal in medical history, physical examination findings, ECGs, or laboratory results. - Participants must have a BMI of 30 kg/m2 to 40 kg/m2 inclusive - Women (not of childbearing potential) and men aged 18 to 60 years, inclusive Exclusion Criteria: - Previous participation in the current study - Inability or unwillingness to comply with protocol-defined restrictions or requirements regarding lifestyle, diet, concomitant medications, or other aspects of the study - Inability to tolerate the oLTT meal or to comply with oLTT testing conditions - Inability to tolerate oral medication - Inability to tolerate venipuncture and/or inadequate venous access - Women who are breastfeeding - Medical Conditions - History of lactose intolerance - Any significant (in the opinion of the investigator) acute or chronic illness - Type 1 or 2 diabetes - Evidence of organ dysfunction or any clinically significant deviation from normal in physical examination, vital signs, ECG, or clinical laboratory determinations beyond what is consistent with the target population - Previous/Concomitant Therapy - Previous exposure to BMS-963272 Other protocol-defined inclusion/exclusion criteria could apply
We strongly recommend you contact BMS to report Side Effects (Adverse Events)
Side Effects (Adverse Events) and other reportable events are defined here
Report Side Effects (Adverse Events) or Product Quality Complaints: Medical Information
